

US EPA ARCHIVE DOCUMENT



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

APR 3 1992

OFFICE OF
PESTICIDES AND TOXIC
SUBSTANCES

MEMORANDUM

SUBJECT: Simazine Meeting with Ciba-Geigy.

TO: Venus Eagle, Review Manager
Special Review and Reregistration Division (H7508W)

FROM: Steven M. Knott, Chemist
Special Review and Registration Section II
Occupational and Residential Exposure Branch
Health Effects Division (H7509C)

Steven M. Knott

THRU: Mark Dow, Ph.D., Section Head
Special Review and Registration Section II
Occupational and Residential Exposure Branch
Health Effects Division (H7509C)

Arthur C. Blosser for MD

Charles L. Trichilo, Ph.D., Chief
Occupational and Residential Exposure Branch
Health Effects Division (H7509C)

Charles L. Trichilo

Ciba-Geigy has requested a meeting (to be held April 7, 1992) with the Agency to discuss their "90-day" response to the September 12, 1991 Data Call In (DCI) for Simazine. The Occupational and Residential Exposure Branch (OREB) has reviewed the "90-day" response and concluded that branch representation at the subject meeting is not warranted.

Ciba-Geigy's response to the DCI requirements that are relevant to occupational exposure is as follows:

Guideline #'s 231 and 232 - "Ciba Geigy has also participated in the development of a generic data base for exposure information. We wish to rely on this in lieu of generating additional exposure data on simazine."

OREB is always willing to review generic or surrogate data submitted to satisfy a particular data requirement. However, the registrant should be aware that if such a submission is rejected, the data requirement must still be satisfied by the deadline specified in the original DCI. Therefore, it would be prudent for the registrant to submit the surrogate data to the Agency as soon as possible. If the surrogate studies have already been submitted to the Agency, they should be referenced by MRID number



in the registrant's exposure assessment or waiver request. If the surrogate studies are available in the published literature, complete copies of the published report and, if possible, the raw data collected during the study should be submitted to the Agency by the registrant.

cc: Correspondence File
Circulation
Simazine File